Header Logo

Philip Bonomi

Concepts (536)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Lung Neoplasms
151
2021
636
15.570
Why?
Carcinoma, Non-Small-Cell Lung
119
2021
321
15.260
Why?
Antineoplastic Combined Chemotherapy Protocols
75
2020
329
7.820
Why?
Antineoplastic Agents
40
2013
252
5.300
Why?
ErbB Receptors
23
2018
73
2.890
Why?
Carcinoma, Squamous Cell
24
2018
180
2.070
Why?
Quinazolines
10
2012
24
2.030
Why?
Paclitaxel
26
2015
74
1.930
Why?
Clinical Trials as Topic
23
2020
337
1.770
Why?
Biomarkers, Tumor
15
2021
198
1.730
Why?
Neoplasm Staging
51
2021
364
1.640
Why?
Cisplatin
40
2016
92
1.580
Why?
Neoplasm Recurrence, Local
19
2019
200
1.540
Why?
Humans
208
2021
29852
1.490
Why?
Carboplatin
23
2015
48
1.290
Why?
Adenocarcinoma
20
2018
194
1.270
Why?
Antibodies, Monoclonal, Humanized
16
2019
119
1.130
Why?
Prognosis
35
2021
874
1.130
Why?
Bevacizumab
10
2016
29
1.130
Why?
Middle Aged
106
2020
9963
1.120
Why?
Aged
100
2019
9621
1.090
Why?
Female
120
2020
16430
1.090
Why?
Pemetrexed
10
2016
14
1.040
Why?
Treatment Outcome
42
2021
3561
1.030
Why?
Weight Gain
3
2016
66
1.030
Why?
Male
108
2019
15871
0.990
Why?
Disease-Free Survival
22
2018
191
0.990
Why?
Clinical Trials, Phase III as Topic
10
2016
28
0.990
Why?
Survival Rate
32
2019
376
0.910
Why?
Taxoids
6
2008
14
0.910
Why?
Etoposide
23
2015
50
0.910
Why?
Protein Kinase Inhibitors
5
2020
55
0.880
Why?
Antibodies, Monoclonal
11
2016
270
0.860
Why?
Apoptosis
13
2009
259
0.850
Why?
Antineoplastic Agents, Phytogenic
9
2008
19
0.850
Why?
Eligibility Determination
2
2020
5
0.820
Why?
Adult
76
2019
8748
0.810
Why?
Survival Analysis
22
2021
310
0.790
Why?
Chemoradiotherapy
4
2015
69
0.750
Why?
Proteomics
3
2020
93
0.750
Why?
Drug Administration Schedule
20
2015
232
0.750
Why?
Adverse Drug Reaction Reporting Systems
1
2020
7
0.720
Why?
Patient Selection
8
2021
234
0.720
Why?
Combined Modality Therapy
31
2011
379
0.710
Why?
Ecosystem
1
2020
27
0.700
Why?
Mutation
11
2018
399
0.700
Why?
Quality of Life
12
2016
677
0.690
Why?
Carcinoma, Small Cell
12
2009
71
0.670
Why?
Drug Resistance, Neoplasm
10
2019
77
0.670
Why?
Small Cell Lung Carcinoma
5
2018
11
0.670
Why?
Gene Dosage
3
2018
24
0.670
Why?
Antineoplastic Agents, Immunological
4
2021
20
0.640
Why?
Molecular Targeted Therapy
3
2018
36
0.550
Why?
Carcinoma, Large Cell
5
2018
15
0.550
Why?
Aged, 80 and over
34
2018
4930
0.520
Why?
Immunotherapy
4
2021
66
0.510
Why?
PTEN Phosphohydrolase
2
2011
10
0.490
Why?
Disease Progression
15
2014
812
0.490
Why?
Kidney Neoplasms
3
2019
61
0.490
Why?
Randomized Controlled Trials as Topic
10
2018
349
0.470
Why?
Polyglutamic Acid
3
2008
4
0.460
Why?
Neoplasms
9
2011
257
0.460
Why?
Follow-Up Studies
15
2019
1859
0.450
Why?
Retrospective Studies
23
2018
3325
0.450
Why?
Carcinoma, Renal Cell
2
2019
36
0.440
Why?
Signal Transduction
5
2013
491
0.430
Why?
Kaplan-Meier Estimate
9
2018
177
0.430
Why?
Erlotinib Hydrochloride
6
2018
16
0.430
Why?
Guanine
7
2015
11
0.420
Why?
Glutamates
7
2015
17
0.420
Why?
Receptor, IGF Type 1
1
2012
19
0.410
Why?
Phosphatidylinositol 3-Kinases
1
2011
47
0.390
Why?
Megestrol
12
1996
12
0.360
Why?
Autoantibodies
3
2021
103
0.350
Why?
Radiotherapy
6
2009
53
0.350
Why?
Fluorouracil
12
2000
75
0.340
Why?
Neovascularization, Pathologic
3
2014
57
0.340
Why?
Cetuximab
4
2013
8
0.330
Why?
Lipoxygenase Inhibitors
8
2003
15
0.330
Why?
Breast Neoplasms
15
1998
352
0.330
Why?
Vinblastine
6
2009
11
0.320
Why?
Drug Delivery Systems
2
2010
39
0.310
Why?
Cyclooxygenase 2
1
2008
33
0.310
Why?
Uterine Cervical Neoplasms
7
1990
51
0.310
Why?
Gastrointestinal Hemorrhage
1
2008
22
0.310
Why?
Carcinoma, Bronchogenic
6
1988
11
0.310
Why?
Indoles
9
2003
51
0.300
Why?
Morpholines
1
2007
15
0.300
Why?
Protein-Tyrosine Kinases
2
2007
21
0.300
Why?
Neoplasm Metastasis
14
2014
110
0.300
Why?
Chromosomes, Human, Pair 7
1
2007
7
0.300
Why?
Proto-Oncogene Proteins c-bcl-2
6
2012
30
0.290
Why?
Macromolecular Substances
1
2007
17
0.290
Why?
Pneumonectomy
6
2012
68
0.290
Why?
Postoperative Complications
6
2019
957
0.280
Why?
Sulfonamides
3
2012
59
0.270
Why?
Adjuvants, Pharmaceutic
1
2005
2
0.270
Why?
Enzyme Inhibitors
3
2004
147
0.270
Why?
Melanoma
1
2006
52
0.260
Why?
Receptors, Progesterone
10
1988
32
0.260
Why?
Lung
4
2018
158
0.260
Why?
Aniline Compounds
3
2012
41
0.250
Why?
United States Food and Drug Administration
2
2020
71
0.240
Why?
Receptors, Estrogen
9
1988
68
0.230
Why?
Proportional Hazards Models
6
2013
346
0.230
Why?
United States
6
2020
2346
0.230
Why?
Antimetabolites, Antineoplastic
2
2000
30
0.220
Why?
Biomarkers
4
2018
704
0.210
Why?
Remission Induction
8
2010
103
0.210
Why?
Angiogenesis Inhibitors
2
2018
18
0.210
Why?
Matrix Metalloproteinase Inhibitors
1
2002
9
0.210
Why?
Matrix Metalloproteinases
1
2002
22
0.200
Why?
Gene Expression Regulation, Neoplastic
3
2018
107
0.200
Why?
Camptothecin
1
2001
3
0.190
Why?
Immunohistochemistry
4
2012
411
0.190
Why?
Thymoma
4
1996
13
0.190
Why?
Thymus Neoplasms
4
1996
12
0.190
Why?
Mediastinal Neoplasms
2
1991
13
0.190
Why?
Drug Evaluation
12
1992
56
0.180
Why?
DNA Methylation
2
2012
128
0.180
Why?
Lymphatic Metastasis
7
2010
87
0.180
Why?
Deoxycytidine
4
2016
39
0.180
Why?
Esophageal Neoplasms
2
2019
46
0.180
Why?
Stakeholder Participation
1
2020
9
0.180
Why?
Diarrhea
3
2007
47
0.180
Why?
Neoadjuvant Therapy
2
2011
63
0.180
Why?
Research Personnel
1
2020
21
0.180
Why?
Receptor, Adenosine A2A
1
2019
3
0.180
Why?
Clinical Trials, Phase II as Topic
4
2009
29
0.170
Why?
Proto-Oncogene Proteins
2
2016
32
0.170
Why?
Salvage Therapy
1
2019
36
0.170
Why?
Regression Analysis
5
2009
299
0.170
Why?
Esophagectomy
1
2019
22
0.170
Why?
Sarcopenia
1
2019
26
0.170
Why?
Receptor, ErbB-2
1
2018
46
0.160
Why?
Tumor Cells, Cultured
10
2003
149
0.160
Why?
Vascular Endothelial Growth Factor A
2
2008
69
0.160
Why?
Apoptosis Regulatory Proteins
2
2010
16
0.160
Why?
Syndecan-1
1
2018
8
0.160
Why?
Immunoassay
1
2018
42
0.150
Why?
Risk Assessment
5
2011
685
0.150
Why?
Nerve Growth Factors
1
2018
49
0.150
Why?
Inflammation Mediators
1
2018
80
0.150
Why?
Models, Statistical
1
1998
133
0.150
Why?
Pteridines
1
2016
1
0.140
Why?
Lung Diseases
1
1997
46
0.140
Why?
Cell Cycle Proteins
1
2016
17
0.140
Why?
Class I Phosphatidylinositol 3-Kinases
2
2018
12
0.140
Why?
Myasthenia Gravis
1
2017
12
0.140
Why?
Cell Division
9
2003
112
0.140
Why?
Palliative Care
2
2015
149
0.140
Why?
Genes, bcl-2
2
2011
3
0.140
Why?
Muscle, Skeletal
1
2019
355
0.140
Why?
Drug Discovery
1
2016
21
0.140
Why?
Cachexia
1
2016
11
0.140
Why?
Radiotherapy Dosage
7
2014
114
0.140
Why?
Exanthema
2
2007
16
0.140
Why?
Cohort Studies
8
2015
1953
0.130
Why?
Cyclin-Dependent Kinase Inhibitor p16
2
2012
21
0.130
Why?
Prostatic Neoplasms
5
1996
110
0.130
Why?
Interleukin-2
2
2009
68
0.130
Why?
Administration, Oral
5
2011
144
0.130
Why?
Isoxazoles
1
1994
16
0.120
Why?
Cell Survival
5
2013
165
0.120
Why?
Predictive Value of Tests
4
2009
532
0.120
Why?
Radiotherapy, Conformal
1
2014
19
0.120
Why?
Body Mass Index
1
2016
425
0.110
Why?
src-Family Kinases
1
2013
8
0.110
Why?
Genes, p16
1
2012
4
0.110
Why?
Triazoles
1
2013
33
0.110
Why?
Thrombocytopenia
2
2012
31
0.110
Why?
Early Detection of Cancer
2
2010
80
0.110
Why?
Vinca Alkaloids
1
2012
1
0.110
Why?
Folate Receptor 1
1
2012
1
0.110
Why?
Folic Acid
1
2012
16
0.110
Why?
Young Adult
3
2014
1969
0.110
Why?
Doxorubicin
7
1996
70
0.110
Why?
Nogalamycin
1
1992
1
0.110
Why?
Platinum Compounds
2
2007
2
0.110
Why?
Area Under Curve
2
2009
67
0.110
Why?
Infusions, Intravenous
7
2006
78
0.110
Why?
Adolescent
3
2014
2334
0.100
Why?
Radiation Injuries
3
2015
34
0.100
Why?
Pyrimidines
2
2019
28
0.100
Why?
C-Peptide
1
2011
7
0.100
Why?
Animals
8
2010
4637
0.100
Why?
Insulin-Like Growth Factor Binding Proteins
1
2011
11
0.100
Why?
Cell Death
3
2003
62
0.100
Why?
Multicenter Studies as Topic
3
2002
77
0.100
Why?
Research Design
4
2016
214
0.100
Why?
Neoplasms, Germ Cell and Embryonal
1
1991
8
0.100
Why?
In Situ Hybridization, Fluorescence
2
2010
32
0.100
Why?
Insulin-Like Growth Factor I
1
2011
58
0.100
Why?
Blood Chemical Analysis
1
2010
13
0.090
Why?
Gene Amplification
1
2010
23
0.090
Why?
Hematologic Tests
1
2010
6
0.090
Why?
Protein Array Analysis
1
2010
10
0.090
Why?
Xanthine Dehydrogenase
1
2010
6
0.090
Why?
Calcium-Calmodulin-Dependent Protein Kinases
1
2010
19
0.090
Why?
Leukocyte Count
4
2017
92
0.090
Why?
Tumor Suppressor Proteins
1
2010
33
0.090
Why?
Inhibitor of Apoptosis Proteins
1
2009
4
0.090
Why?
Microtubule-Associated Proteins
1
2009
21
0.090
Why?
Radiotherapy Planning, Computer-Assisted
2
2014
68
0.090
Why?
Diphtheria Toxin
1
2009
2
0.090
Why?
Treatment Failure
3
2016
161
0.090
Why?
Colonic Neoplasms
7
1988
67
0.080
Why?
Neutropenia
1
2009
21
0.080
Why?
Smoking
3
2016
194
0.080
Why?
Pancreatic Neoplasms
4
2003
151
0.080
Why?
Forecasting
2
2001
117
0.080
Why?
B7-H1 Antigen
2
2021
14
0.080
Why?
Cyclophosphamide
6
1996
56
0.080
Why?
Organoplatinum Compounds
3
2002
5
0.080
Why?
Time Factors
5
2018
1641
0.080
Why?
Fatigue
1
2009
63
0.080
Why?
Piperidines
1
2008
32
0.080
Why?
Lymph Nodes
1
2009
71
0.080
Why?
Logistic Models
2
2007
410
0.080
Why?
Interferon Type I
2
1986
19
0.080
Why?
Celecoxib
1
2008
5
0.080
Why?
Peptic Ulcer
1
2008
6
0.080
Why?
Megestrol Acetate
9
1988
9
0.080
Why?
In Situ Hybridization
1
2008
51
0.080
Why?
Razoxane
1
1988
2
0.080
Why?
Receptors, Tumor Necrosis Factor
1
2008
33
0.080
Why?
Granulocyte Colony-Stimulating Factor
2
1998
12
0.080
Why?
Anemia
1
2009
99
0.080
Why?
Epothilones
1
2007
2
0.080
Why?
Drug Screening Assays, Antitumor
3
2003
13
0.070
Why?
Algorithms
4
2010
401
0.070
Why?
Aneuploidy
1
2007
3
0.070
Why?
Tomography, X-Ray Computed
3
2014
778
0.070
Why?
Pyrazoles
1
2008
50
0.070
Why?
Models, Theoretical
2
2005
94
0.070
Why?
DNA Mutational Analysis
1
2007
57
0.070
Why?
Piperazines
1
1988
93
0.070
Why?
Carcinoma
3
1996
59
0.070
Why?
Dactinomycin
2
2003
7
0.070
Why?
Radiotherapy, Adjuvant
2
2011
65
0.070
Why?
Polymerase Chain Reaction
1
2007
166
0.070
Why?
Calcium
3
2002
498
0.070
Why?
Analysis of Variance
4
2011
327
0.070
Why?
Antigens, Neoplasm
2
2021
44
0.070
Why?
Endpoint Determination
1
2006
28
0.070
Why?
Proteasome Inhibitors
1
2005
3
0.070
Why?
Boronic Acids
1
2005
4
0.070
Why?
Bortezomib
1
2005
5
0.070
Why?
Drug Approval
1
2006
31
0.070
Why?
Pyrazines
1
2005
11
0.070
Why?
TNF-Related Apoptosis-Inducing Ligand
1
2005
8
0.070
Why?
Ligands
1
2005
58
0.070
Why?
Dose-Response Relationship, Drug
4
2011
456
0.070
Why?
Cause of Death
2
2009
64
0.070
Why?
Multivariate Analysis
4
2011
332
0.070
Why?
Cyclooxygenase Inhibitors
1
2005
39
0.070
Why?
Cytosol
3
2002
63
0.070
Why?
Pilot Projects
5
2000
403
0.060
Why?
Membrane Glycoproteins
1
2005
103
0.060
Why?
Positron-Emission Tomography
1
2005
91
0.060
Why?
Tamoxifen
5
1988
30
0.060
Why?
Chemotherapy, Adjuvant
3
2011
95
0.060
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2005
107
0.060
Why?
Radiographic Image Interpretation, Computer-Assisted
1
2004
27
0.060
Why?
Tumor Necrosis Factor-alpha
1
2005
223
0.060
Why?
Cell Line, Tumor
3
2013
273
0.060
Why?
Oxidative Stress
2
2002
131
0.060
Why?
Prospective Studies
4
2018
1824
0.060
Why?
Radiometry
1
2004
39
0.060
Why?
Hematologic Diseases
2
2002
14
0.060
Why?
Digestive System Neoplasms
1
1984
5
0.060
Why?
Prostate
3
1997
32
0.060
Why?
Protein Synthesis Inhibitors
1
2003
9
0.060
Why?
Aminoquinolines
1
2003
1
0.060
Why?
Organic Chemicals
1
2003
8
0.060
Why?
Recurrence
2
2016
355
0.060
Why?
Sensitivity and Specificity
4
2009
558
0.060
Why?
Pyrroles
1
2003
23
0.060
Why?
Epidermal Growth Factor
1
2003
32
0.060
Why?
Health Status Indicators
1
2004
78
0.060
Why?
Oligonucleotide Array Sequence Analysis
2
2002
59
0.060
Why?
Aminoacridines
1
1983
2
0.060
Why?
Pyridines
2
2019
45
0.060
Why?
Genetic Therapy
1
2004
91
0.050
Why?
Imaging, Three-Dimensional
1
2004
222
0.050
Why?
Injections, Intravenous
3
1999
58
0.050
Why?
Lymphocytes
2
2017
110
0.050
Why?
Antibiotics, Antineoplastic
2
2003
24
0.050
Why?
Random Allocation
5
2002
143
0.050
Why?
Image Processing, Computer-Assisted
2
2012
221
0.050
Why?
Neoplasm Invasiveness
1
2002
78
0.050
Why?
Radiation Pneumonitis
2
2015
4
0.050
Why?
Mitomycins
4
1989
4
0.050
Why?
Health Status
1
2003
230
0.050
Why?
Programmed Cell Death 1 Receptor
1
2021
19
0.050
Why?
Antineoplastic Agents, Alkylating
1
2001
14
0.050
Why?
Observer Variation
1
2021
119
0.050
Why?
Genome
1
2000
15
0.050
Why?
Adrenalectomy
1
2000
2
0.050
Why?
Tomography, Emission-Computed
1
2000
11
0.050
Why?
Dyspnea
2
2015
36
0.050
Why?
Adrenal Gland Neoplasms
1
2000
12
0.050
Why?
Maximum Tolerated Dose
2
2011
20
0.050
Why?
DNA Damage
3
2008
30
0.050
Why?
Calcium Signaling
1
2002
171
0.040
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
1997
10
0.040
Why?
Furans
1
2019
5
0.040
Why?
Genes, Tumor Suppressor
1
1999
13
0.040
Why?
Interferon-beta
1
1999
7
0.040
Why?
Oncogenes
1
1999
13
0.040
Why?
Methotrexate
3
1989
42
0.040
Why?
Retinoblastoma Binding Proteins
1
2018
1
0.040
Why?
Platelet Count
3
1989
22
0.040
Why?
Free Radical Scavengers
1
1999
13
0.040
Why?
North America
1
2018
39
0.040
Why?
Neoplasm Grading
1
2018
53
0.040
Why?
Ubiquitin-Protein Ligases
1
2018
41
0.040
Why?
Liver Neoplasms
3
2005
106
0.040
Why?
Interferons
1
1998
14
0.040
Why?
Case-Control Studies
2
2010
643
0.040
Why?
Testicular Neoplasms
1
1978
23
0.040
Why?
Neoplasms, Hormone-Dependent
3
1986
5
0.040
Why?
Echinomycin
1
1998
1
0.040
Why?
Trimetrexate
1
1998
1
0.040
Why?
Ovarian Neoplasms
1
1978
49
0.040
Why?
DNA, Neoplasm
2
1996
23
0.040
Why?
Tumor Suppressor Protein p53
1
2018
91
0.040
Why?
Cell Differentiation
2
1996
150
0.040
Why?
Phenotype
1
2018
364
0.040
Why?
Age Factors
3
2012
854
0.040
Why?
Drug Therapy, Combination
4
1999
245
0.040
Why?
Agranulocytosis
1
1996
5
0.040
Why?
Administration, Intravenous
1
2016
28
0.040
Why?
Surveys and Questionnaires
1
2002
1187
0.030
Why?
Fadrozole
1
1996
1
0.030
Why?
Body Weight
1
2017
132
0.030
Why?
Genetic Predisposition to Disease
1
2018
446
0.030
Why?
Neutrophils
1
2017
117
0.030
Why?
Cell Transformation, Neoplastic
1
1996
36
0.030
Why?
Longitudinal Studies
2
1998
1462
0.030
Why?
Flow Cytometry
3
2003
202
0.030
Why?
Stem Cells
1
1996
49
0.030
Why?
Pneumonia
1
1996
67
0.030
Why?
Hemoptysis
1
2015
8
0.030
Why?
Esophagitis
1
2015
11
0.030
Why?
Cough
1
2015
12
0.030
Why?
Chest Pain
1
2015
24
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2015
17
0.030
Why?
Drug Tolerance
1
1995
12
0.030
Why?
Thorax
1
1995
12
0.030
Why?
Teniposide
1
1995
2
0.030
Why?
Gallium
1
1995
4
0.030
Why?
Imides
1
1995
2
0.030
Why?
Isoquinolines
1
1995
14
0.030
Why?
DNA Repair
2
2008
7
0.030
Why?
Drugs, Investigational
1
1995
9
0.030
Why?
Feasibility Studies
1
1995
230
0.030
Why?
Vincristine
2
1992
27
0.030
Why?
Drug Resistance
1
1994
58
0.030
Why?
Comorbidity
1
2016
504
0.030
Why?
Optics and Photonics
1
1994
2
0.030
Why?
S Phase
1
1994
10
0.030
Why?
Mobility Limitation
1
2015
97
0.030
Why?
Reactive Oxygen Species
1
1994
130
0.030
Why?
Cell Nucleus
1
1994
80
0.030
Why?
Proto-Oncogene Proteins c-met
1
2013
4
0.030
Why?
Protein Kinase C beta
1
2013
8
0.030
Why?
Proteins
2
1985
71
0.030
Why?
Diet
1
2015
172
0.030
Why?
Receptor Protein-Tyrosine Kinases
1
2013
8
0.030
Why?
Gene Rearrangement
1
2013
11
0.030
Why?
HSP90 Heat-Shock Proteins
1
2013
7
0.030
Why?
Protein Kinase C
1
2013
47
0.030
Why?
Enzyme Activation
1
2013
112
0.030
Why?
Protein Binding
1
2013
125
0.030
Why?
Biopsy
1
1994
239
0.030
Why?
Phosphorylation
1
2013
159
0.030
Why?
Procarbazine
2
1989
3
0.030
Why?
Cell Membrane
1
2013
106
0.030
Why?
Radiography, Thoracic
1
2012
28
0.030
Why?
Oligopeptides
1
2012
30
0.030
Why?
Menogaril
1
1992
1
0.030
Why?
Child, Preschool
1
1994
654
0.030
Why?
Epigenesis, Genetic
1
2012
75
0.030
Why?
Illinois
1
2012
241
0.030
Why?
Genotype
1
2013
409
0.030
Why?
Preoperative Care
2
2009
135
0.020
Why?
Activities of Daily Living
1
2015
507
0.020
Why?
Rectal Neoplasms
2
1988
18
0.020
Why?
Misonidazole
1
1990
2
0.020
Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
9
0.020
Why?
Serum
1
2010
9
0.020
Why?
Tandem Mass Spectrometry
1
2010
27
0.020
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2002
155
0.020
Why?
Antibodies, Neoplasm
1
2010
10
0.020
Why?
DNA Modification Methylases
1
2010
3
0.020
Why?
Death-Associated Protein Kinases
1
2010
4
0.020
Why?
DNA Repair Enzymes
1
2010
6
0.020
Why?
Monomeric GTP-Binding Proteins
1
2010
6
0.020
Why?
Immunoenzyme Techniques
1
2010
40
0.020
Why?
CpG Islands
1
2010
34
0.020
Why?
Cadherins
1
2010
31
0.020
Why?
Promoter Regions, Genetic
1
2010
81
0.020
Why?
Neoplasm Proteins
1
2010
53
0.020
Why?
RNA, Messenger
2
2002
325
0.020
Why?
Antigens, CD
1
2010
102
0.020
Why?
Adaptor Proteins, Signal Transducing
1
2010
78
0.020
Why?
Lymph Node Excision
1
2009
27
0.020
Why?
Drug Synergism
1
1989
66
0.020
Why?
Recombinant Fusion Proteins
1
2009
31
0.020
Why?
Vindesine
2
1986
3
0.020
Why?
Nervous System Neoplasms
1
1988
3
0.020
Why?
Endocrine System Diseases
1
1988
3
0.020
Why?
Soft Tissue Neoplasms
2
1988
51
0.020
Why?
California
1
2008
31
0.020
Why?
Electrophoresis, Polyacrylamide Gel
2
1985
35
0.020
Why?
Molecular Weight
2
1985
44
0.020
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2008
1
0.020
Why?
Creatine Kinase
1
1988
33
0.020
Why?
Adenocarcinoma, Bronchiolo-Alveolar
1
2007
3
0.020
Why?
Bone Neoplasms
2
1988
106
0.020
Why?
Piroxicam
1
1987
5
0.020
Why?
Receptors, Steroid
1
1987
3
0.020
Why?
Altretamine
1
1986
1
0.020
Why?
Receptors, Cell Surface
1
1986
50
0.020
Why?
Radiation Protection
1
2005
5
0.020
Why?
Menopause
3
1996
135
0.020
Why?
Head and Neck Neoplasms
2
1984
135
0.020
Why?
Models, Biological
2
1999
347
0.020
Why?
Radiopharmaceuticals
1
2005
53
0.020
Why?
Fluorodeoxyglucose F18
1
2005
39
0.020
Why?
Rosaniline Dyes
1
1985
1
0.020
Why?
Nomograms
1
2005
5
0.020
Why?
Prostatic Hyperplasia
1
1985
12
0.020
Why?
Relative Biological Effectiveness
1
2004
5
0.020
Why?
Body Burden
1
2004
9
0.020
Why?
Radiation Dosage
1
2004
32
0.020
Why?
Bone Marrow
1
1985
78
0.020
Why?
Skin Neoplasms
1
2005
67
0.010
Why?
Hepatectomy
1
1984
54
0.010
Why?
Women's Health
1
2006
247
0.010
Why?
Nucleosomes
1
2003
3
0.010
Why?
DNA Fragmentation
1
2003
7
0.010
Why?
Tumor Stem Cell Assay
1
2003
6
0.010
Why?
Stomach Neoplasms
1
1984
30
0.010
Why?
Caspases
1
2003
33
0.010
Why?
Cell Culture Techniques
1
2003
45
0.010
Why?
Molybdenum
2
1980
21
0.010
Why?
Sarcoma
1
1986
133
0.010
Why?
Amsacrine
1
1983
2
0.010
Why?
Sleep Stages
1
2002
34
0.010
Why?
Carcinoma, Hepatocellular
1
1983
33
0.010
Why?
U937 Cells
1
2002
2
0.010
Why?
HL-60 Cells
1
2002
14
0.010
Why?
Arachidonate 5-Lipoxygenase
1
2002
8
0.010
Why?
Fluorescent Dyes
1
2002
55
0.010
Why?
Reproducibility of Results
1
2004
803
0.010
Why?
Blood Platelets
1
1982
50
0.010
Why?
Paraneoplastic Endocrine Syndromes
1
1981
2
0.010
Why?
Mitochondria
1
2002
84
0.010
Why?
Spin Labels
1
2001
2
0.010
Why?
Nitrogen Oxides
1
2001
2
0.010
Why?
Cyclic N-Oxides
1
2001
5
0.010
Why?
Membrane Potentials
1
2002
193
0.010
Why?
Carcinoma, Intraductal, Noninfiltrating
1
1981
9
0.010
Why?
Amides
1
2001
21
0.010
Why?
Apudoma
1
1981
2
0.010
Why?
Psychometrics
1
2002
264
0.010
Why?
DNA Replication
1
2000
12
0.010
Why?
Dexamethasone
1
2000
48
0.010
Why?
Genes, cdc
1
1999
1
0.010
Why?
Ribonucleases
1
1999
9
0.010
Why?
DNA, Complementary
1
1999
28
0.010
Why?
Blotting, Western
1
1999
175
0.010
Why?
Free Radicals
1
1999
9
0.010
Why?
Hematopoiesis
1
1999
13
0.010
Why?
Reperfusion Injury
1
1999
8
0.010
Why?
Demography
1
1999
78
0.010
Why?
Myelodysplastic Syndromes
1
1999
38
0.010
Why?
Intercalating Agents
1
1998
1
0.010
Why?
Risk Factors
1
2004
2467
0.010
Why?
Amiloride
1
1997
7
0.010
Why?
Fura-2
1
1997
4
0.010
Why?
Fluoresceins
1
1997
8
0.010
Why?
Trypsin
1
1997
6
0.010
Why?
Dimethyl Sulfoxide
1
1996
3
0.010
Why?
DNA
1
1997
123
0.010
Why?
Mitosis
1
1996
9
0.010
Why?
G2 Phase
1
1996
4
0.010
Why?
Fatal Outcome
1
1996
60
0.010
Why?
Hydrogen-Ion Concentration
1
1997
149
0.010
Why?
Prostaglandins
1
1996
4
0.010
Why?
Genes, Homeobox
1
1996
5
0.010
Why?
Telomerase
1
1996
10
0.010
Why?
Inflammation
1
1999
347
0.010
Why?
Postoperative Care
1
1997
127
0.010
Why?
Cell Count
1
1996
97
0.010
Why?
Biological Evolution
1
1996
23
0.010
Why?
Ifosfamide
1
1995
14
0.010
Why?
Progesterone
2
1988
21
0.010
Why?
Naphthalimides
1
1995
2
0.010
Why?
Adenine
1
1995
4
0.010
Why?
Organophosphonates
1
1995
5
0.010
Why?
Double-Blind Method
1
1996
522
0.010
Why?
Isoelectric Focusing
2
1985
4
0.010
Why?
Aging
1
2002
1630
0.010
Why?
HIV Infections
1
1999
997
0.010
Why?
Radiation-Sensitizing Agents
1
1990
10
0.010
Why?
Mitomycin
1
1988
12
0.010
Why?
Microscopy, Electron
1
1988
75
0.010
Why?
Patient Participation
1
1988
51
0.000
Why?
Isoenzymes
1
1988
54
0.000
Why?
Axilla
1
1987
13
0.000
Why?
Killer Cells, Natural
1
1987
93
0.000
Why?
Colon
1
1988
149
0.000
Why?
Monocytes
1
1987
111
0.000
Why?
Lymphocyte Activation
1
1987
215
0.000
Why?
Indicators and Reagents
1
1985
13
0.000
Why?
Actuarial Analysis
1
1984
14
0.000
Why?
Risk
1
1984
217
0.000
Why?
Electrophoresis
1
1983
17
0.000
Why?
Radiography
1
1985
678
0.000
Why?
Maytansine
1
1982
3
0.000
Why?
Streptozocin
1
1982
6
0.000
Why?
Carcinoembryonic Antigen
1
1982
6
0.000
Why?
Leukopenia
1
1982
9
0.000
Why?
Cytoplasmic Granules
1
1981
9
0.000
Why?
Castration
1
1981
4
0.000
Why?
Pelvic Neoplasms
1
1981
4
0.000
Why?
Charcoal
1
1980
2
0.000
Why?
Dextrans
1
1980
6
0.000
Why?
Centrifugation, Density Gradient
1
1980
13
0.000
Why?
Tritium
1
1980
14
0.000
Why?
Uterus
1
1980
14
0.000
Why?
Brain Neoplasms
1
1981
134
0.000
Why?
In Vitro Techniques
1
1980
215
0.000
Why?
Bonomi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (536)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_